Fundraising Fox

CytoAgents

Pittsburgh, US · Founded 2018 · Delaware corporation · 1 known investors

CytoAgents is a clinical-stage biopharmaceutical company developing therapies for the life-threatening symptoms of Cytokine Release Syndrome (CRS), an immune overreaction causing systemic inflammation. It is led by a team of drug development experts and a scientific advisory board focused on immunology and clinical drug development.

BiotechHealthtech

Founders & leadership

TW
Teresa Whalen, RPhin
CM
Catherine MottNamed on SEC filing
TW
Teresa WhalenChief Executive Officer
AM
Anthony McCarleyNamed on SEC filing
JF
John FriedmanNamed on SEC filing
SM
Stanley MarksNamed on SEC filing

Investors · 1

Boston Harbor AngelsBoston · $250K – $1.5M

Reported raises · per SEC filings

Form D private placements

$13.1M disclosed across 2 rounds · 2021–2023

▶$7MraisedMay 2023 · 23 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Roy PriebExecutive Officer
  • Robert L FerrisDirector
  • Stanley MarksDirector
  • Teresa WhalenExecutive Officer, Director
  • Anthony McCarleyDirector
  • Catherine MottDirector
Offering amount
$15.2M
Amount sold
$7M
First sale
May 2023
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.1MraisedAug 2021 · 23 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Catherine MottDirector
  • Teresa WhalenExecutive Officer, Director
  • Anthony McCarleyDirector
  • John FriedmanDirector
  • Stanley MarksDirector
Offering amount
$6.5M
Amount sold
$6.1M
Minimum investment
$10K
First sale
Jul 2021
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap
Incyte Corporation5 shared keywordsIncyte is a global biopharmaceutical company that develops medicines across hematology, oncology, and inflammation and autoimmunity, with clinical programs spanning areas such as dermatology. It focuses on research and development of treatments for patients.
Cullinan Therapeutics5 shared keywordsCullinan Therapeutics is a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer, with a pipeline that includes CD19- and BCMA-targeted T cell engagers. Its focus areas include immune modulation approaches for conditions such as refractory lupus (SLE) and rheumatoid arthritis.
Kyverna Therapeutics4 shared keywordsKyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset. The company conducts clinical trials for multiple autoimmune conditions globally.

Companies competing with CytoAgents for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2021$2M
National Institutes of Health (NIH)National Institutes of HealthPhase II2020$1.7M

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does CytoAgents do?
CytoAgents is a clinical-stage biopharmaceutical company developing therapies for the life-threatening symptoms of Cytokine Release Syndrome (CRS), an immune overreaction causing systemic inflammation. It is led by a team of drug development experts and a scientific advisory board focused on immunology and clinical drug development.
Who are CytoAgents's investors?
CytoAgents's investors include Boston Harbor Angels.
How much funding has CytoAgents raised?
CytoAgents has disclosed $13.1M raised across 2 rounds.
Where is CytoAgents headquartered?
CytoAgents is headquartered in Pittsburgh, US.